



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 17TH FEBRUARY 2021

PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr T McKenzie (TM)	GP East Lancs
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Harding (CH)	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
Dr G Perera	Consultant Paediatrician, ELHT (for Item 025)
DR S Garg	Consultant Cardiologist, ELHT (for Item 026)

2021/021: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
--------------------	---------------------------

2021/022: DECLARATION OF INTEREST

SR – interest in diabetes

None declared by other members – relevant to agenda items.

2021/023: MINUTES OF JANUARY Teams MEETING:

Accepted as a correct record.

2021/024: MATTERS ARISING:

2019/131: Treatment of Vitamin B12 Deficiency Draft – pathway to be brought to ELMMB in early 2021.

2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta® - JV arranging meeting in early 2021.

2020/092: Drug Safety Update – Denosumab – To be brought to ELMMB in early 2021 and include endocrinologists.

2020/107: Adrenaline Auto Injector Position Statement & Patient Information Leaflet – To be brought to ELMMB in early 2021.

2021/012: LSCMMG Recommendations – LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway – comments have been sent to LSCMMG.

2021/013: Joint Committee of CCGs Commissioning Decisions – LR confirmed recent JCCCG approvals are in line with ELMMB. The JCCCG decisions on last month's ELMMB agenda can be added to ELMMB website.

2021/016: Goserelin Shared Care Guideline – amended 10.8mg shared care to be brought to next meeting.

2021/018: NICE Recommendations (from December) Liraglutide for managing overweight & obesity (TA664) – approved in line with NICE. Access to MDT tier 3 weight management services to be followed up with commissioners.

2021/025: NEW PRODUCT REQUEST – MELATONIN (CIRCADIN®) TABLETS

Dr G Perera, representing general paediatrics, community developmental paediatrics and ELCAS, presented this item.

Unlicensed melatonin capsules used by ELHE are being withdrawn. Circadin® tablets provide the most suitable and cost effective alternative.

Paediatrics are requesting that the melatonin preparation for use in ELHE be changed accordingly to off label use of Circadin®. They also request the traffic light status is changed from Red to Amber for use in children with neurodevelopmental disorders to improve sleep quality.

An amber traffic light will be in line with the rest of Lancashire and reduce the number of hospital visits for families.

The change to Circadin® is supported by ELMMB alongside the use of sleep diaries and regular assessment/review by secondary care. The paediatrics policy for prescribing of melatonin will need to be updated to Circadin® and a shared care guidance made available to GPs.

VG to ask paediatric pharmacist to work with Dr Perera to update policy and provide shared care document.

Resolved: Circadin® tablets approved for use for paediatrics to replace unlicensed melatonin capsules.
Traffic Light: AMBER

2021/026: FREE OF CHARGE PRODUCT REQUEST – BEMPEDOIC ACID

Requested and presented by Dr Garg, Consultant Cardiologist, for the treatment of hypercholesterolaemia when standard therapy has failed to reduce lipid levels, and patients are not eligible for PCSK9's.

The company are offering to provide bempedoic acid as part of a free of charge scheme for patients with a high unmet clinical need in advance of NICE guidance. Dr Garg considered that for at least one patient there is currently no suitable alternative. Concerns were expressed by ELMMB members that NICE may not approve or may approve in a different cohort of patients. It was noted that the SMC had not approved its use. As a NICE

TA is due imminently it was considered prudent to wait for this before any decision on the general use of bempedoic acid was made.

If there is a patient with urgent clinical need it can be considered by the trust via chair of ELMMB for individual use via FOC scheme.

Resolved: Bempedoic acid not currently approved for use. Await NICE TA.

2021/027: SARILUMAB IN THE TREATMENT OF COVID-19 ON CRITICAL CARE

For information – Sarilumab is being used as part of treatment of some patients with Covid-19 on critical care unit in line with UK Clinical Commissioning Policy.

Resolved: Sarilumab use acknowledged.

2021/028: LSCMMG CONSULTATIONS (FOR MARCH LSCMMG)

Neuropathic Pain Pathway for Primary Care – Updated – concern was expressed that for severe pain the pathway was a referral for specialist review however, there is no reference or guidance offering management options while waiting for the referral appointment.

Ketamine for Chronic Non-Cancer Pain - New Medicine Assessment – supportive of the black traffic light recommendation.

Insulin Lispro (Lyumjev®) – New Medicine Assessment – concerns were expressed that although it decreased post prandial glucose levels there was no changes to HbA1c. The benefits for Type II diabetes do not seem to be as good as for Type I diabetes. Suggest it should be specialist recommendation.

Comments to be sent to LSCMMG

2021/029: LSCMMG Recommendations

Amiodarone & Dronedronone Shared Care Guidelines – Accepted for use in ELHE.

Dr Garg was asked the purpose of repeat ECG for patients on amiodarone. He felt it was to observe effectiveness in AF. A discussion took place regarding referral back of current patients on Amiodarone some of whom are elderly and have been on this for a long period of time. Dr Garg advised that the GP should consider how long patient has been taking it, whether they have adverse effects, if there are other options for treatment and the views of the patient to guide a decision.

2021/030: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS

No meeting

2021/031: FORMULARY UPDATES

Synalar N® cream & ointment discontinued – remove from formulary

Resolved: Formulary to be updated as above.

2021/032: NON-CANCER PAIN – MANAGED OPIOID REDUCTION PATHWAY

To resolve concerns re consistency of documents on the website the Non-Cancer Pain – Managed Opioid reduction Pathway brings together relevant information in one document. The opioid reduction information in the LSCMMG document appendix has been removed.

Resolved: Non-Cancer Pain – Managed Opioid Reduction Pathway approved.

2021/033: NICE RECOMMENDATIONS (from January)

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [TA668] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669) is not recommended as an option by NICE.

Traffic Light: BLACK

Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Brolucizumab for treating wet age-related macular degeneration (TA672 fast track) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned - Blueteq form required

Traffic Light: RED

2021/034: EAMS

Pemigatinib - Treatment of adult patients with cholangiocarcinoma (cancer of the bile ducts) that has spread locally or to other parts of the body and has a specific genetic abnormality (fibroblast growth factor receptor 2 fusion or rearrangement) and has returned after or not responded to treatment with chemotherapy.

Acknowledged

STANDING ITEMS

2021/035: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – January 2021

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 17th March 2021 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 17TH FEBRUARY 2021

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed.	LR/JV	Mar 21
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - meeting to be arranged to consider place on primary care guidelines	JV	Mar 21
2020/092	Drug Safety Update – Denosumab Invite representatives from rheumatology, MSK & medicine for older people to next meeting	CW/AG/LR	Mar 21
2020/107	Adrenaline Auto Injector Position Statement & Patient Information Leaflet – discuss policies & procedures in schools with LCC	JV	Mar 21
2021/016	ELHE: GOSERELIN SHARED CARE GUIDELINE – also amend shared care for 10.8mg implant	VG	Feb 21
2021/025	New Product Request – Circadin® Tablets – update paediatric melatonin policy and provide shared care	VG	Mar 21